{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:57:20Z","timestamp":1790899040965,"version":"4.1.0"},"reference-count":76,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Deanship of Graduate Studies and Scientific Research at Qassim University"},{"id":[{"id":"https:\/\/ror.org\/01wsfe280","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hypertriglyceridemia is a well-recognized contributor to residual atherosclerotic cardiovascular disease risk and a predisposing factor for acute pancreatitis. Despite the availability of pharmacologic agents and lifestyle interventions, patients with severe and refractory hypertriglyceridemia often fail to achieve adequate control. Recent advances in the molecular understanding of triglyceride metabolism have driven the development of targeted therapies that selectively modulate key regulatory pathways. This study sought to provide an overview of triglyceride regulation, the atherogenic role of remnant lipoproteins, and clinical evidence of emerging triglyceride-lowering therapies. Lipoprotein metabolism is regulated by a complex network of regulatory proteins that include lipoprotein lipase (LPL), apolipoproteins such as apolipoprotein C-III (ApoC-III), and angiopoietin-like proteins (ANGPTLs). Targeting these proteins in the metabolic cascade has shown promising results in reducing triglyceride levels. Emerging therapies such as antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) directed against ApoC-III (volanesorsen, olezarsen, and plozasiran), inhibitors of ANGPTL3 (evinacumab and zodasiran), and fibroblast growth factor 21 (FGF-21) analogs (pegozafermin) have demonstrated substantial triglyceride-lowering efficacy. These agents have achieved reductions in triglyceride levels of up to 80% in clinical trials. Additionally, preliminary evidence suggests that these agents may also reduce the incidence of acute pancreatitis and improve cardiometabolic risk profiles, although dedicated trials are still needed to confirm these outcomes. The therapeutic landscape for hypertriglyceridemia is rapidly evolving. Integrating these novel agents into clinical practice will require individualized treatment plans, sustained lifestyle modification, and careful safety monitoring.<\/jats:p>","DOI":"10.3390\/ijms27083573","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:14:12Z","timestamp":1776352452000},"page":"3573","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Current and Emerging Pharmacological Therapies for Hypertriglyceridemia"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3346-1223","authenticated-orcid":false,"given":"Ibrahim S.","family":"Alhomoud","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, Qassim University, Buraydah 51452, Qassim, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jacl.2025.02.008","article-title":"Epidemiology and longitudinal course of chylomicronemia: Insights from NHANES and a large health care system","volume":"19","author":"Saadatagah","year":"2025","journal-title":"J. Clin. Lipidol."},{"key":"ref_2","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: An Endocrine Society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/ATVBAHA.107.160192","article-title":"Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome","volume":"28","author":"Adiels","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.jacc.2020.10.008","article-title":"Remnant Cholesterol, Not LDL Cholesterol, Is Associated with Incident Cardiovascular Disease","volume":"76","author":"Subirana","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/phar.2851","article-title":"Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies","volume":"43","author":"Alhomoud","year":"2023","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"L21","DOI":"10.1093\/eurheartj\/sui082","article-title":"What is the relationship between risk factor reduction and degree of weight loss?","volume":"7","author":"Mertens","year":"2005","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM199108153250703","article-title":"The Effects on Plasma Lipoproteins of a Prudent Weight-Reducing Diet, with or without Exercise, in Overweight Men and Women","volume":"325","author":"Wood","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jacl.2023.05.099","article-title":"Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association","volume":"17","author":"Kirkpatrick","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jacl.2025.03.013","article-title":"Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association","volume":"19","author":"Javed","year":"2025","journal-title":"J. Clin. Lipidol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lo, C.C., and Coschigano, K.T. (2020). ApoB48 as an Efficient Regulator of Intestinal Lipid Transport. Front. Physiol., 11.","DOI":"10.3389\/fphys.2020.00796"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e14742","DOI":"10.15252\/emmm.202114742","article-title":"When fat meets the gut-focus on intestinal lipid handling in metabolic health and disease","volume":"14","author":"Wit","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1161\/CIRCRESAHA.123.323284","article-title":"VLDL Biogenesis and Secretion: It Takes a Village","volume":"134","author":"Ginsberg","year":"2024","journal-title":"Circ. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jacl.2022.08.009","article-title":"Guidance for the diagnosis and treatment of hypolipidemia disorders","volume":"16","author":"Bredefeld","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1056\/NEJMe2402653","article-title":"Shooting the Messenger to Treat Hypertriglyceridemia","volume":"390","author":"Watts","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100578","DOI":"10.1016\/j.jlr.2024.100578","article-title":"APOA5 deficiency causes hypertriglyceridemia by reducing amounts of lipoprotein lipase in capillaries","volume":"65","author":"Yang","year":"2024","journal-title":"J. Lipid Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e2200093","DOI":"10.1002\/adbi.202200093","article-title":"The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity","volume":"6","author":"Wen","year":"2022","journal-title":"Adv. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.12997\/jla.2024.13.1.2","article-title":"Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors","volume":"13","author":"Tomlinson","year":"2024","journal-title":"J. Lipid Atheroscler."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MED.0000000000000857","article-title":"APOC3 siRNA and ASO therapy for dyslipidemia","volume":"31","author":"Chebli","year":"2024","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Zimodro, J.M., Rizzo, M., and Gouni-Berthold, I. (2025). Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review. Pharmaceuticals, 18.","DOI":"10.3390\/ph18020147"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1172\/JCI30889","article-title":"Atherogenic remnant lipoproteins: Role for proteoglycans in trapping, transferring, and internalizing","volume":"117","author":"Mahley","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"119114","DOI":"10.1016\/j.atherosclerosis.2025.119114","article-title":"Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA","volume":"403","author":"Brinton","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"E493","DOI":"10.1152\/ajpendo.00195.2021","article-title":"Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8","volume":"321","author":"Davies","year":"2021","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1021\/acschembio.0c00954","article-title":"The Angiopoietin-Like Protein 3 and 8 Complex Interacts with Lipoprotein Lipase and Induces LPL Cleavage","volume":"16","author":"Jin","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"119235","DOI":"10.1016\/j.atherosclerosis.2025.119235","article-title":"Angiopoietin-like protein inhibitors: Promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia","volume":"405","author":"Farhoudi","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/ATVBAHA.123.320175","article-title":"Remnant Cholesterol, Not LDL Cholesterol, Explains Peripheral Artery Disease Risk Conferred by apoB: A Cohort Study","volume":"44","author":"Pedersen","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","article-title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: A UK Biobank study","volume":"44","author":"Adiels","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nrcardio.2013.140","article-title":"Demystifying the management of hypertriglyceridaemia","volume":"10","author":"Watts","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacl.2018.10.006","article-title":"Severe hypertriglyceridemia is primarily polygenic","volume":"13","author":"Dron","year":"2019","journal-title":"J. Clin. Lipidol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Balk, E.M., Adams, G.P., Langberg, V., Halladay, C., Chung, M., Lin, L., Robertson, S., Yip, A., Steele, D., and Smith, B.T. (2016). Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review. Evid. Rep. Technol. Assess. (Full Rep.), 1\u20131252.","DOI":"10.23970\/AHRQEPCERTA223"},{"key":"ref_36","first-page":"e673","article-title":"Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association","volume":"140","author":"Wilson","year":"2019","journal-title":"Circulation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid","volume":"40","author":"Mason","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients with Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"22C","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy","volume":"99","author":"Guyton","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","article-title":"Target Populations for Novel Triglyceride-Lowering Therapies","volume":"85","author":"Nordestgaard","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s11883-023-01140-z","article-title":"Updates in Drug Treatment of Severe Hypertriglyceridemia","volume":"25","author":"Schwarz","year":"2023","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic. Acid. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrcardio.2018.3","article-title":"Advances in lipid-lowering therapy through gene-silencing technologies","volume":"15","author":"Nordestgaard","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Alhomoud, I.S. (2025). Emerging therapies targeting lipoprotein(a): The next frontier in cardiovascular risk reduction. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1727918"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"100475","DOI":"10.1016\/j.jlr.2023.100475","article-title":"Apolipoprotein C3: Form begets function","volume":"65","author":"Bornfeldt","year":"2024","journal-title":"J. Lipid. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jacl.2023.03.007","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial","volume":"17","author":"Witztum","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Alexander","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_52","unstructured":"U.S. Food and Drug Administration (2025, July 10). Tryngolza, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218614s000lbl.pdf."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1093\/cvr\/cvad177","article-title":"Exploring apolipoprotein C-III: Pathophysiological and pharmacological relevance","volume":"119","author":"Packard","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk","volume":"392","author":"Watts","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","article-title":"Evinacumab in homozygous familial hypercholesterolaemia: Long-term safety and efficacy","volume":"45","author":"Gaudet","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: A phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.jacl.2023.12.001","article-title":"Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3","volume":"18","author":"Zimerman","year":"2024","journal-title":"J. Clin. Lipidol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/eurjpc\/zwae090","article-title":"Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: An analysis from the TRANSLATE-TIMI 70 trial","volume":"31","author":"Zimerman","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/CRD.0000000000000625","article-title":"Pegozafermin Is a Potential Master Therapeutic Regulator in Metabolic Disorders: A Review","volume":"33","author":"Bailey","year":"2023","journal-title":"Cardiol. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: From bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","article-title":"A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21","volume":"29","author":"Kliewer","year":"2019","journal-title":"Cell. Metab."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.tem.2024.02.001","article-title":"Current status and future perspectives of FGF21 analogues in clinical trials","volume":"35","author":"Chui","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: A randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/j.jacl.2024.04.086","article-title":"Study Design of a Phase 3 Randomized Controlled Trial Evaluating the Efficacy and Safety of Pegozafermin in Patients with Severe Hypertriglyceridemia","volume":"18","author":"Hartsfield","year":"2024","journal-title":"J. Clin. Lipidol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Albekery, M.A., Alhomoud, I.S., Alabdulathim, L.S., Almajed, M.A., Alobaid, A.A., Alomair, M.K., Al Shehab, S.A., Alhasan, K.A., and Al Hamid, A. (2025). Underutilization of albuminuria screening in adults with diabetes mellitus or hypertension: A systematic review and meta-analysis. BMC Nephrol., 27.","DOI":"10.1186\/s12882-025-04672-5"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.2147\/JMDH.S560362","article-title":"ApoB Testing in Dyslipidemia Management: Knowledge and Practices of Healthcare Providers in Saudi Arabia","volume":"18","author":"Altuwalah","year":"2025","journal-title":"JMDH"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/phar.4607","article-title":"Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management","volume":"44","author":"Alhomoud","year":"2024","journal-title":"Pharmacotherapy"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1139\/cjpp-2025-0038","article-title":"Repurposing Incretin Therapies: A Narrative Review of Emerging Indications Across Cardiometabolic, Liver, Kidney, Neurological, Psychiatric, and Other Systems","volume":"103","author":"Alhomoud","year":"2025","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","article-title":"Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study","volume":"16","author":"Oral","year":"2022","journal-title":"J. Clin. Lipidol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/8\/3573\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T08:12:55Z","timestamp":1776931975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/8\/3573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":76,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ijms27083573"],"URL":"https:\/\/doi.org\/10.3390\/ijms27083573","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]}}}